GSK and Sanofi ready to start human trials on COVID-19 potential vaccine

GSK and Sanofi ready to start human trials on COVID-19 potential vaccine

The relevant result to be available by the end of the year

The middle of the week came with good news from GlaxoSmithKline and Sanofi. The largest vaccine maker globally and the French drugmaker announced that their potential COVID-19 #vaccine would undergo human testing.

It all started in April when the two companies joined forces to develop a protein-based #COVID-19 vaccine, which so far showed promising results in clinical trials. According to them, the human clinical trial is designed to assess the vaccine's safety, tolerability, and immune response. If all goes well, the first results will be available by December. The clinical trial will occur at eleven sites across the US, and more than 400 people will take part.

Combined, GSK and Sanofi have the largest developing and manufacturing capability in the world, and their target is to produce 1 billion doses of vaccine in 2021.

To speed up the vaccine's development and to secure 100 million doses, the US government gave the companies $2.1 billion. Also, the UK is said to receive up to 60 million doses of vaccine if proven effective by undergoing trials.

The market reacted positively to the news, and GSK stock price gained more than 2%, while Sanofi added over 1%.

While you are here, don't forget to check-out our Corona Blend!

Sources: theguardian.com, finance.yahoo.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.